<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1870-7203</journal-id>
<journal-title><![CDATA[Acta médica Grupo Ángeles]]></journal-title>
<abbrev-journal-title><![CDATA[Acta méd. Grupo Ángeles]]></abbrev-journal-title>
<issn>1870-7203</issn>
<publisher>
<publisher-name><![CDATA[Grupo Ángeles, Servicios de Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1870-72032024000400281</article-id>
<article-id pub-id-type="doi">10.35366/117516</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Prevalencia de enfermedad por hígado graso asociada a disfunción metabólica en el Hospital Angeles Pedregal en un periodo de tres años]]></article-title>
<article-title xml:lang="en"><![CDATA[Prevalence of fatty liver disease associated with metabolic dysfunction in the Hospital Angeles Pedregal over a three-year period]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gallegos Garza]]></surname>
<given-names><![CDATA[Adriana Cecilia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bautista Martínez]]></surname>
<given-names><![CDATA[Brenda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García Abarca]]></surname>
<given-names><![CDATA[Rebeca Saraí]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santibañez Silva]]></surname>
<given-names><![CDATA[Violeta]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz Greene]]></surname>
<given-names><![CDATA[Enrique Juan]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Angeles Pedregal Servicio de Patología ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad La Salle Hospital Angeles Pedregal Servicio Social. Facultad Mexicana de Medicina]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad del Valle de México Hospital Angeles Pedregal Servicio Social. Facultad de Medicina]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidad La Salle Hospital Angeles Pedregal Facultad Mexicana de Medicina]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2024</year>
</pub-date>
<volume>22</volume>
<numero>4</numero>
<fpage>281</fpage>
<lpage>285</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1870-72032024000400281&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1870-72032024000400281&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1870-72032024000400281&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  la enfermedad por hígado graso asociada a disfunción metabólica (MAFLD) es la causa más común de enfermedad hepática crónica. En México se estima una prevalencia de 14.4% con diagnóstico por ultrasonido. Actualmente, la biopsia hepática es el estándar de oro para el diagnóstico, definiéndose la esteatosis hepática como la acumulación de triglicéridos en el citoplasma de los hepatocitos.  Objetivo:  determinar la prevalencia de esteatohepatitis, fibrosis y cirrosis hepática en un hospital privado de la Ciudad de México.  Material y métodos:  se realizó un estudio observacional, retrospectivo, transversal y descriptivo en el que se revisó una base de datos en la que se estudiaron 67 biopsias hepáticas realizadas en el Servicio de Anatomía Patológica dl Hospital Angeles Pedregal, en el periodo comprendido de enero de 2021 a diciembre de 2023.  Resultados:  de las biopsias hepáticas analizadas, 44.77% tuvieron esteatohepatitis; de las cuales, 50% presentaron grado I, 30% grado II y 10% grados III y IV, respectivamente. El 53.73% de los casos presentaron fibrosis (n = 36); de los cuales 27.77% fueron grado 1, 11.11% grado 2, 11.11% grado 3 y 50% grado 4 o cirrosis.  Conclusiones:  la MAFLD es la causa más común de enfermedad hepática crónica y es la principal causa de morbilidad y mortalidad relacionadas a enfermedades hepáticas en México. La alta prevalencia de esteatohepatitis, fibrosis y cirrosis en el presente estudio demuestra la importancia de su diagnóstico oportuno y prevención, para garantizar una mejor calidad de vida para los pacientes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common cause of chronic liver disease. In Mexico, an estimated prevalence of 14.4% is diagnosed through ultrasound. Liver biopsy serves as the gold standard for diagnosis, defining hepatic steatosis as the accumulation of triglycerides in the hepatocyte cytoplasm.  Objective:  the present study aimed to determine the prevalence of steatohepatitis, fibrosis, and liver cirrhosis in a private hospital in Mexico City.  Material and methods:  an observational, retrospective, cross-sectional, and descriptive study was conducted, reviewing a database of 67 liver biopsies at Hospital Angeles del Pedregal Pathology Department from January 2021 to December 2023.  Results:  among the analyzed liver biopsies, 44.77% exhibited steatohepatitis. Of these, 50% were grade I, 30% were grade II, and 10% were grades III and IV, respectively. Fibrosis was present in 53.73% of patients (n = 36), from which 27.77% were grade 1, 11.11% grade 2, 11.11% grade 3, and 50% were grade 4, also categorized as cirrhosis.  Conclusions:  MAFLD is the most common cause of chronic liver disease and is the leading cause of liver disease-related morbidity and mortality in Mexico. The high prevalence of steatohepatitis, fibrosis, and cirrhosis in the present study demonstrates the importance of its timely diagnosis and prevention to ensure a better quality of life for patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[esteatohepatitis]]></kwd>
<kwd lng="es"><![CDATA[esteatosis]]></kwd>
<kwd lng="es"><![CDATA[fibrosis]]></kwd>
<kwd lng="es"><![CDATA[cirrosis]]></kwd>
<kwd lng="es"><![CDATA[respuesta inflamatoria]]></kwd>
<kwd lng="es"><![CDATA[biopsia hepática]]></kwd>
<kwd lng="en"><![CDATA[steatohepatitis]]></kwd>
<kwd lng="en"><![CDATA[steatosis]]></kwd>
<kwd lng="en"><![CDATA[fibrosis]]></kwd>
<kwd lng="en"><![CDATA[cirrhosis]]></kwd>
<kwd lng="en"><![CDATA[inflammatory response]]></kwd>
<kwd lng="en"><![CDATA[liver biopsy]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rinella]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Lazarus]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
<name>
<surname><![CDATA[Ratziu]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Francque]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Sanyal]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kanwal]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A multisociety Delphi consensus statement on new fatty liver disease nomenclature]]></article-title>
<source><![CDATA[Ann Hepatol]]></source>
<year>2023</year>
<volume>78</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1966-86</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Romero-Gómez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-alcoholic steatohepatitis]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2022</year>
<volume>159</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>388-95</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
<name>
<surname><![CDATA[Chuah]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Rajaram]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Ratnasingam]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vethakkan]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): a state-of-the-art review]]></article-title>
<source><![CDATA[J Obes Metab Syndr]]></source>
<year>2023</year>
<volume>32</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>197-213</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Flores]]></surname>
<given-names><![CDATA[YN]]></given-names>
</name>
<name>
<surname><![CDATA[Amoon]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Su]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Velazquez-Cruz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez-Palacios]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Salmerón]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum lipids are associated with nonalcoholic fatty liver disease: a pilot case-control study in Mexico]]></article-title>
<source><![CDATA[Lipids Health Dis]]></source>
<year>2021</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>136</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pouwels]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sakran]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Leal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pintar]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss]]></article-title>
<source><![CDATA[BMC Endocr Disord]]></source>
<year>2022</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>63</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Velarde-Ruiz]]></surname>
<given-names><![CDATA[VJA]]></given-names>
</name>
<name>
<surname><![CDATA[García-Jiménez]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[García-Zermeño]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Morel-Cerda]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Aldana-Ledesma]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Castro-Narro]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Complicaciones extrahepáticas de la enfermedad por hígado graso no alcohólico: impacto más allá del hígado]]></article-title>
<source><![CDATA[Rev Gastroenterol Mex]]></source>
<year>2019</year>
<volume>84</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>472-81</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caro-Sabido]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Larrosa-Haro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eficacia de la intervención nutricia y de la actividad física en niños y adolescentes con hígado graso no alcohólico asociado a obesidad: revisión sistemática exploratoria]]></article-title>
<source><![CDATA[Rev Gastroenterol Mex]]></source>
<year>2019</year>
<volume>84</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>185-94</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Extrahepatic manifestations of nonalcoholic fatty liver disease]]></article-title>
<source><![CDATA[Gut Liver]]></source>
<year>2020</year>
<volume>14</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>168-78</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[ZH]]></given-names>
</name>
<name>
<surname><![CDATA[Argo]]></surname>
<given-names><![CDATA[CK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How to identify the patient with nonalcoholic steatohepatitis who will progress to cirrhosis]]></article-title>
<source><![CDATA[Gastroenterol Clin North Am]]></source>
<year>2020</year>
<volume>49</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>45-62</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caballeria]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Torán]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8221;Epidemia de esteatosis hepática: un análisis desde la atención primaria&#8221;]]></article-title>
<source><![CDATA[Aten Primaria]]></source>
<year>2019</year>
<volume>51</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>525-6</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Flores]]></surname>
<given-names><![CDATA[YN]]></given-names>
</name>
<name>
<surname><![CDATA[Amoon]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Su]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Velazquez-Cruz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez-Palacios]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Salmerón]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum lipids are associated with nonalcoholic fatty liver disease: a pilot case-control study in Mexico]]></article-title>
<source><![CDATA[Lipids Health Dis]]></source>
<year>2021</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>136</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bernal-Reyes]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Castro-Narro]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Malé-Velázquez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Carmona-Sánchez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[González-Huezo]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[García-Juárez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consenso mexicano de la enfermedad por hígado graso no alcohólico]]></article-title>
<source><![CDATA[Rev Gastroenterol Mex]]></source>
<year>2019</year>
<volume>84</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>69-99</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saiman]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Duarte-Rojo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rinella]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fatty liver disease: diagnosis and stratification]]></article-title>
<source><![CDATA[Annu Rev Med]]></source>
<year>2022</year>
<volume>73</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>529-44</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of MAFLD and NAFLD diagnostic criteria in real world]]></article-title>
<source><![CDATA[Liver Int]]></source>
<year>2020</year>
<volume>40</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2082-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ackerman]]></surname>
<given-names><![CDATA[LV]]></given-names>
</name>
<name>
<surname><![CDATA[Rosai]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Capítulo 13: Hígado]]></article-title>
<source><![CDATA[Rosai y Ackerman Patología Quirúrgica]]></source>
<year>2013</year>
<edition>10ma</edition>
<page-range>878-83</page-range><publisher-loc><![CDATA[Ciudad de México ]]></publisher-loc>
<publisher-name><![CDATA[Amolca]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Powell]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[VWS]]></given-names>
</name>
<name>
<surname><![CDATA[Rinella]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-alcoholic fatty liver disease]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2021</year>
<volume>397</volume>
<numero>10290</numero>
<issue>10290</issue>
<page-range>2212-24</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graffigna]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Catoira]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Soutelo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Azpelicueta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Berg]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Perel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnóstico de esteatosis hepática por métodos clínicos, bioquímicos y por imágenes]]></article-title>
<source><![CDATA[Rev Argent Endocrinol Metab]]></source>
<year>2017</year>
<volume>54</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>37-46</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Papatheodoridi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cholongitas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis of non-alcoholic fatty liver disease (NAFLD): current concepts]]></article-title>
<source><![CDATA[Curr Pharm Des]]></source>
<year>2019</year>
<volume>24</volume>
<numero>38</numero>
<issue>38</issue>
<page-range>4574-86</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
